NEKTAR THERAPEUTICS
NKTR evidence brief
What we can confirm
- BioSniper Score:
- 4.4 / 10
- Market Cap:
- $2.58B
- Lead Asset:
- NKTR-255 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for NKTR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NKTR
Nektar Therapeutics (NKTR) is a clinical-stage biotechnology company focused on developing novel immunology therapies, with its lead drug candidate rezpegaldesleukin (REZPEG) now in Phase 3 trials for atopic dermatitis and alopecia areata.
Key risk: No near-term pivotal data
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Tracking 2 pipeline candidates · 7 clinical trials for NEKTAR THERAPEUTICS.
Nektar Therapeutics (NKTR) is a clinical-stage biotechnology company focused on developing novel immunology therapies, with its lead drug candidate rezpegaldesleukin (REZPEG) now in Phase 3 trials for atopic dermatitis and alopecia areata.
- Lead drug rezpegaldesleukin (REZPEG) is in Phase 3 trials for moderate-to-severe atopic dermatitis and alopecia areata [news · published 2026-08-27].
- Phase 3 ZENITH AD program initiated in July 2026, with initial topline data expected in mid-2028 [news · published 2026-07-21].
- Company reported a strong cash position with cash runway to 2028 [news · published 2026-08-14].
- Phase 2b data for REZPEG in atopic dermatitis and alopecia areata were presented at the 2026 EADV Congress, including 6-month off-treatment results [news · published 2026-09-30].
- REZPEG has received Fast Track regulatory status [pipeline].
What works
- Strong cash position provides financial runway to 2028, supporting ongoing Phase 3 trials without near-term financing pressure [news · published 2026-08-14].
- Phase 2b data showed clinically meaningful efficacy and favorable safety in a 393-patient study, forming the basis for the Phase 3 program [news · published 2026-07-21].
- Positive physician reception and mechanistic data from multi-omic biomarker sub-studies add scientific credibility to the Treg proliferation approach [news · published 2026-09-30].
What to weigh
- Initial Phase 3 topline data are not expected until mid-2028, meaning no pivotal readout for approximately two years [news · published 2026-07-21].
- The competitive landscape includes 15 competitors, with Pfizer and Eli Lilly already in Phase 3 for similar indications [pipeline].
- Extended timelines for key data readouts create uncertainty about long-term value inflection points [news · published 2026-08-14].
From the filings
Quoted directly from source documents.
Phase 3 trials initiated for REZPEG in atopic dermatitis
“Two global registrational Phase 3 trials initiated in ZENITH AD program”
News · July 21, 2026
Initial Phase 3 topline data expected in mid-2028
“Initial Phase 3 Topline Data Expected In Mid-2028”
News · July 21, 2026
Cash runway to 2028
“$1.02B cash runway to 2028”
News · August 14, 2026
Phase 2b data presented at EADV 2026
“data from its Phase 2b rezpegaldesleukin trials in atopic dermatitis and alopecia areata were presented in three oral sessions at the 2026 EADV Congress in Vienna”
News · September 30, 2026
Catalyst timeline
- 2026-07-21 · Phase 3 ZENITH AD program initiation — Two global registrational trials started for rezpegaldesleukin in atopic dermatitis.
- 2026-09-30 · Phase 2b data presentation at EADV 2026 — New 6-month off-treatment results and mechanistic data presented.
- 2028-06-30 · Initial Phase 3 topline data expected — First pivotal efficacy readout from ZENITH AD program anticipated.
Risks & what to watch (3)›
Key risks
- No near-term pivotal data — Phase 3 topline data not expected until mid-2028, creating a multi-year wait for key efficacy readouts [news · published 2026-07-21].
- Intense competitive landscape — 15 competitors in atopic dermatitis/alopecia areata, including Pfizer and Eli Lilly in Phase 3 [pipeline].
- Dependence on single drug — Company's near-term prospects rely heavily on rezpegaldesleukin success across two indications [news · published 2026-08-27].
What to watch
- Enrollment progress and any interim updates from the ZENITH AD Phase 3 program [news · published 2026-07-21].
- Regulatory interactions and potential Fast Track benefits for rezpegaldesleukin [pipeline].
- Competitive developments from Pfizer and Eli Lilly in the same indications [pipeline].
- Any additional mechanistic or durability data releases from ongoing biomarker sub-studies [news · published 2026-09-30].
Sources: Catalysts · News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run NEKTAR THERAPEUTICS through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NEKTAR THERAPEUTICS facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
0 buys · 10 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
208
Total value held
$1.88B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 4,303,188 | $309.6M |
| bvf inc/il | 2,559,595 | $184.2M |
| two seas capital lp | 1,959,178 | $141.0M |
| vanguard capital management llc | 1,197,055 | $86.1M |
| two sigma investments, lp | 930,741 | $67.0M |
| prosight management, lp | 735,000 | $52.9M |
| blackrock, inc. | 692,650 | $49.8M |
| morgan stanley | 659,387 | $47.4M |
| armistice capital, llc | 578,000 | $41.6M |
| invesco ltd. | 567,458 | $40.8M |
Showing top 10 of 208 institutional holders of NEKTAR THERAPEUTICS. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 12.9%
- Days to cover
- 4.3
- Shares short
- 3,663,438
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NKTR short interestGovernance
Frequently asked questions
What is the AI investment thesis for NEKTAR THERAPEUTICS?
Nektar Therapeutics (NKTR) is a clinical-stage biotechnology company focused on developing novel immunology therapies, with its lead drug candidate rezpegaldesleukin (REZPEG) now in Phase 3 trials for atopic dermatitis and alopecia areata.
What is NEKTAR THERAPEUTICS's lead drug candidate?
NEKTAR THERAPEUTICS's most advanced tracked candidate is NKTR-255 (Phase 1) for Head and Neck Squamous Cell Carcinoma.
Who is the CEO of NEKTAR THERAPEUTICS?
Mr. Howard W. Robin is the chief executive officer of NEKTAR THERAPEUTICS (NKTR).
Where is NEKTAR THERAPEUTICS headquartered?
NEKTAR THERAPEUTICS (NKTR) is headquartered in San Francisco, CA, United States.
What therapeutic areas does NEKTAR THERAPEUTICS focus on?
NEKTAR THERAPEUTICS develops therapies across Oncology, Immunology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.